Loading news...
Maryland State Retirement and Pension System cut its position in shares of ICU Medical, Inc. (NASDAQ: ICUI) by 50.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,549 shares of the medical instruments supplier's stock after selling 3,684 shares during the period.
Inscription Capital LLC lifted its position in ICU Medical, Inc. (NASDAQ: ICUI) by 407.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,365 shares of the medical instruments supplier's stock after purchasing an additional 6,718 shares during the quarter. Inscription
ICU Medical, Inc. (ICUI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ICU Medical, Inc. (NASDAQ: ICUI - Get Free Report) has received an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has
SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 44th Annual J.P.
ICU Medical has emerged from a painful post-Smiths Medical integration process, shifting focus from remediation to growth and margin expansion. Essentially divesting the low-margin IV solutions business to Otsuka and launching new products can drive gross margin improvement toward 43%-45%. ICUI should achieve sustained EBITDA margins above 20% and double-digit FCF growth, supporting deleveraging and potential capital returns.
Aaron Wealth Advisors LLC bought a new stake in ICU Medical, Inc. (NASDAQ: ICUI) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,342 shares of the medical instruments supplier's stock, valued at approximately $521,000. Several other large investors
Federated Hermes Inc. cut its position in ICU Medical, Inc. (NASDAQ: ICUI) by 8.9% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 185,494 shares of the medical instruments supplier's stock after selling 18,034 shares during the period. Federated Hermes Inc. owned approximately 0.75% of ICU
Creative Planning grew its stake in shares of ICU Medical, Inc. (NASDAQ: ICUI) by 11.6% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,416 shares of the medical instruments supplier's stock after buying an additional 667 shares during the quarter.
SAN CLEMENTE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference being held in New York, December 2-4, 2025. ICU Medical's fireside chat will be on Thursday, December 4, 2025 at 10:00 a.m. PT (1:00 p.m. ET). Company management will also be participating in one-on-one meetings on Thursday, December 4, 2025.
Envestnet Asset Management Inc. lessened its stake in ICU Medical, Inc. (NASDAQ: ICUI) by 4.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 19,364 shares of the medical instruments supplier's stock after selling 905 shares during the period. Envestnet Asset Management Inc. owned about 0.08%
ICU Medical (ICUI) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.59 per share a year ago.
ICU Medical, Inc. ( ICUI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Vivek Jain - CEO & Chairman of the Board Brian Bonnell - CFO & Treasurer Conference Call Participants Deirdre Thomson - ICR Inc. Jayson Bedford - Raymond James & Associates, Inc., Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Lawrence Solow - CJS Securities, Inc. Jason Bednar - Piper Sandler & Co., Research Division Presentation Operator Good afternoon, everyone, and welcome to ICU Medical's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that today's event is being recorded.
SAN CLEMENTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2025.
AlphaQuest LLC boosted its holdings in ICU Medical, Inc. (NASDAQ: ICUI) by 3,058.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,516 shares of the medical instruments supplier's stock after buying an additional 1,468 shares during the
ICU Medical, Inc. (NASDAQ: ICUI - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has
SAN CLEMENTE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2025 earnings release and conference call.
ICU Medical, Inc. (NASDAQ:ICUI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Vivek Jain - CEO & Chairman of the Board Presentation Unknown Analyst Did you give me the disclosure? Did you say anything more?
ICUI faces an FDA recall of its Plum Duo Infusion System over software flaws, though devices remain in use, pending fixes.